CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization.
0
CIRM-Funded Clinical Trials
Photo Credit: UCLA Broad Stem Cell Research Center
Funding Opportunities
Visit our Funding Opportunities page to apply for clinical trial research funding.
Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
---|---|---|---|---|---|---|
Arthritis Osteoarthritis |
Dr. Kristen A Johnson | Calibr | Phase 1 | Completed | 60 | |
Bladder or Urinary Tract Disorder | James Yoo | Wake Forest University Health Sciences | Phase 1 | Not yet recruiting | 10 | |
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes | Immusoft Corporation | Phase 1 | Launching | N/A | |
COVID-19 Respiratory Disorders |
Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
COVID-19 Respiratory Disorders |
William van der Touw | Celularity Inc. | Phase 1/2 | Closed | 86 | |
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui | University of California, San Diego | Phase 1/2 | Active, not recruiting | 6 | |
Danon Disease Pediatrics |
Dr. Jonathan Schwartz | Rocket Pharmaceuticals, Inc. | Phase 2 | Launching | N/A | |
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer | University of California, Davis | Phase 2 | Recruiting | 55 | |
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B. Kohn Leslie Meltzer |
University of California, Los Angeles Orchard Therapeutics |
Phase 2 | Completed | 10 | |
HIV/AIDS Immune Disease |
Steven G. Deeks | University of California, San Francisco | Phase 1/2 | Recruiting | 18 | |
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn | University of California, Los Angeles | Phase 1/2 | Recruiting | 16 | |
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk | St. Jude Children’s Research Hospital | Phase 1/2 | Suspended | 28 | |
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 | Recruiting | 40 | |
Immune Disease | Dr. Jonathan Benjamin | ImmPACT-Bio, Inc. | Phase 1/2 | Launching | N/A | |
Immune Disease Leukocyte Adhesion Deficiency |
Kinnari Patel | Rocket Pharmaceuticals, Inc. | Phase 1/2 | Completed | 9 | |
Immune Disease | Maria Grazia Roncarolo | Tr1X Inc. | Phase 1 | Launching | N/A | |
Lupus, Systemic Lupus Erythematosus (SLE) | Dr. Vaneet Sandhu | Fate Therapeutics, Inc. | Phase 1 | Launching | N/A | |
Muscle Injury | Peter C Belafsky | University of California, Davis | Phase 1/2 | Recruiting | 62 | |
Neurological Disorders Other |
Prof. Olivia Kim-McManus | University of California, San Diego | Phase 1/2 | Launching | N/A | |
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn | University of California, Los Angeles | Phase 1 | Active, not recruiting | 4 | |
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 26 | |
Solid Tumors | Dr. Dennis J Slamon | University of California, Los Angeles | Phase 1 | Completed | 46 |